Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by β-lactam physiological concentrations over time: An in vitro pharmacodynamic simulation

Microbial Drug Resistance

Volumn 14, Issue 1, 2008, Pages 13-21

  Cafini, Fabio ^a   Aguilar, Lorenzo ^a   Sevillano, David ^a   Giménez, Maria Jose ^a   Alou, Luis ^a   Fenoll, Asuncion ^b   Echevarría, Olatz ^a   Torrico, Martha ^a   González, Natalia ^a   Coronel, Pilar ^c   Prieto, Jose ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Tedec Meiji Farma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFIXIME; CEFUROXIME; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; PENICILLIN G; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; COLONY FORMING UNIT; COMPUTER MODEL; GENE MUTATION; IN VITRO STUDY; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; PENICILLIN-BINDING PROTEINS; PEPTIDYL TRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS;

EID: 41149087744     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2008.0783     Document Type: Article

References (39)

1. Abgueguen, P., E. Azoulay-Dupuis, V. Noel, P. Moine, V. Rieux, B. Fantin, and J.P. Bedos. 2007. Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics. Antimicrob. Agents Chemother. 51:208-214.
2. Alou, L., M.J. Gimenez, D. Sevillano, L. Aguilar, F. Cafini, O. Echeverria, E. Perez-Trallero, and J. Prieto. 2006. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J. Antimicrob. Chemother. 58:349-358.
3. Amezaga, M.R., P.E. Carter, P. Cash, and H. McKenzie. 2002. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J. Clin. Microbiol. 40:3313-3318.
4. Andrews, J.M. 1999. Microbiological assays. In D.S. Reeves, R. Wise, J.M. Andrews, et al., (eds.), Clinical antimicrobial assays, 1st edition. Oxford University Press, Oxford, pp. 35-44.
5. Austin, D.J., K.G. Kristinsson, and R.M. Anderson. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl. Acad. Sci. USA 96:1152-1156.
6. Azoulay-Dupuis, E., P. Moine, J.P. Bedos, V. Rieux, and E. Vallee. 1996. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob. Agents Chemother. 40:941-946.
7. Ball, P., F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D.E. Low, E. Rubinstein, R. Wise; and Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. 2002. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49:31-40.
8. Baquero F. 2005. Evolution and the nature of time. Int. Microbiol. 8:81-91.
9. Barbhaiya, R.H., U.A. Shukla, C.R. Gleason, W.C. Shyu, R.B. Wilber, and K.A. Pittman. 1990. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob. Agents Chemother. 34:1204-1209.
10. Burkhardt, O., K. Borner, N. von der Hoh, P. Koppe, M.W. Pletz, C.E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
11. Cafini, F., R. del Campo, L. Alou, D. Sevillano, M.I. Morosini, F. Baquero, J. Prieto; and Spanish Pneumococcal Network (G03/103). 2006. Alterations of the penicillin-binding proteins and murM alleles of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin in Spain. J. Antimicrob. Chemother. 57:224-229.
12. Clinical and Laboratory Standards Institute/NCCLS. 2005. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI/NCCLS document M100-S15. CLSI, Wayne, PA.
13. Dagan, R., K.P. Klugman, W.A. Craig, and F. Baquero. 2001. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47:129-140.
14. Doern, G.V. 2001. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33 Suppl 3:S187-S192.
15. Finn, A., A. Straughn, M. Meyer, and J. Chubb. 1987. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm. Drug Dispos. 8:519-526.
16. Garcia-Rey, C., A. Fenoll, L. Aguilar, and J. Casal. 2004. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J. Antimicrob. Chemother. 54:465-471.
17. Gillespie, S.H. 2001. Antibiotic resistance in the absence of selective pressure. Int. J. Antimicrob. Agents 17:171-176.
18. Gillespie, S.H., L.L. Voelker, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8:79-84.
19. Gray, B.M., and H.C. Dillon, Jr. 1986. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr. Infect. Dis. 5:201-207.
20. Klepser, M.E., M.N. Marangos, K.B. Patel, D.P. Nicolau, R. Quintiliani, and C.H. Nightingale. 1995. Clinical pharmaco-kinetics of newer cephalosporins. Clin. Pharmacokinet. 28:361-384.
21. Knudsen, J.D., I. Odenholt, H. Erlendsdottir, M. Gottfredsson, O. Cars, N. Frimodt-Moller, F. Espersen, K.G. Kristinsson, and S. Gudmundsson. 2003. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob. Agents Chemother. 47:2499-2506.
22. Levin, B.R., M. Lipsitch, V. Perrot, S. Schrag, R. Antia, L. Simonsen, N.M. Walker, and F.M. Stewart. 1997. The population genetics of antibiotic resistance. Clin. Infect. Dis. 24 Suppl 1:S9-S16.
23. Linares, J.F., I. Gustafsson, F. Baquero, and J.L. Martinez. 2006. Antibiotics as intermicrobial signaling agents instead of weapons. Proc. Natl. Acad. Sci. USA 103:19484-19489.
24. MacGowan, A.P., C.A. Rogers, H.A. Holt, and K.E. Bowker. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
25. MacGowan, A.P., and R. Wise. 2001. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48 Suppl 1:17-28.
26. Mulford, D., M. Mayer, and G. Witt. 2000. Effect of age and gender on the pharmacokinetics of cefditoren. In Abstracts of the fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Abstract 310. American Society for Microbiology, Washington, DC.
27. Mulford, D., M. Mayer, and G. Witt. 2000. Effect of renal impairment on the pharmacokinetic of cefditoren. In Abstracts of the fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Abstract 311. American Society for Microbiology, Washington, DC.
28. Nuermberger, E.L., and W.R. Bishai. 2004. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin. Infect. Dis. 38 Suppl 4:S363-S371.
29. Pan, X.S., J. Ambler, S. Mehtar, and L.M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
30. Perez-Trallero, E., C. Garcia-de-la-Fuente, C. Garcia-Rey, F. Baquero, L. Aguilar, R. Dal-Re, J. Garcia-de-Lomas; and Spanish Surveillance Group for Respiratory Pathogens. 2005. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob. Agents Chemother. 49:1965-1972.
31. Rozen, D.E., L. McGee, B.R. Levin, and K.P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:412-416.
32. Schrag, S.J., B. Beall, and S.F. Dowell. 2000. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin. Microbiol. Rev. 13:588-601.
33. Sevillano, D., L. Aguilar, L. Alou, M.J. Gimenez, O. Echevarria, F. Cafini, E. Valero, A. Fenoll, and J. Prieto. 2006. Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations. J. Antimicrob. Chemother. 58:794-801.
34. Sevillano, D., A. Calvo, M.J. Gimenez, L. Alou, L. Aguilar, E. Valero, A. Carcas, and J. Prieto. 2004. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125mg sustained-release co-amoxiclav formulation. J. Antimicrob. Chemother. 54: 1148-1151.
35. Sommers, D.K., M. van Wyk, P.E. Williams, and S.M. Harding. 1984. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob. Agents Chemother. 25:344-347.
36. Soriano, F., and V. Rodriguez-Cerrato. 2002. Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract. J. Antimicrob. Chemother. 50 Suppl S2:51-58.
37. Trzcinski, K., C.M. Thompson, A.M. Gilbey, C.G. Dowson, and M. Lipsitch. 2006. Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J. Infect. Dis. 193:1296-1303.
38. Vree, T.B., E. Dammers, and P.S. Exler. 2003. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J. Antimicrob. Chemother. 51:373-378.
39. Widdowson, C.A., P.V. Adrian, and K.P. Klugman. 2000. Acquisition of chloramphenicol resistance by the linearization and integration of the entire staphylococcal plasmid pC194 into the chromosome of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:393-395.